Category: Today’s Highlights

Learning More About Moderna’s Virtual Vaccine Day

Learning More About Moderna’s Virtual Vaccine Day

Moderna Therapeutics Virtual Vaccine Day On April 7, 2020 Moderna Therapeutics (MRNA) announced that it will host its virtual Vaccine Day for analysts and investors at 8:00 a.m. EST on Tuesday, April 14th. Moderna informed that during its first Vaccine Day Stéphane Bancel Chief Executive Officer and Tal Zaks Chief Medical Officer as well as key opinion . . . This content is for paid …
Encouraging News About the COVID-19 Outbreak. See Also: Important News from Gilead

Encouraging News About the COVID-19 Outbreak. See Also: Important News from Gilead

COVID-19 at Its Peak? The number of deaths from the COVID-19 outbreak in NYC are expected to peak soon. This expectation is coming from a prestigious trustworthy Washington University. The news also stated that Italy is turning the corner if it has not already turned it. They are reporting the lowest death toll for two weeks. France also reported a slowing of daily deaths while …
Two Companies Coronavirus Will Fail To Disrupt

Two Companies Coronavirus Will Fail To Disrupt

Vertex and Regeneron Will Survive the Coronavirus Market Vertex We picked Vertex (VRTX) on March 18, 2011 at $44.39. The stock closed at $218 at the end of 2019. It rallied in mid-February reaching $247.78 then the unexpected and unseen novel coronavirus started infecting the world. Our 2020 target is still $280. We decided upon this new target in . . . This content is …
Why We Are Still Optimistic. See Also: Inovio’s Good News

Why We Are Still Optimistic. See Also: Inovio’s Good News

COVID-19 and the Nation's Hospitals Disagreeable news with regard to the nation's hospitals is their unpreparedness to face a sudden crisis, let alone an unexpected and unprecedented pandemic. The system the hospitals are running on has been causing problems for a some time now, not just since the Coronavirus pandemic. Since the COVID-19 cases have been rushed to hospitals many unwarranted, unacceptable, intolerable and dangerous …
Good News for Exelixis and for Japanese Renal Cell Carcinoma Patients

Good News for Exelixis and for Japanese Renal Cell Carcinoma Patients

Exelixis, Takeda and Japanese RCC Patients Today we learned from Exelixis (EXEL) that Takeda Pharmaceutical Company Limited, which is responsible for the clinical development and commercialization of Exelixis' oncology drug  CABOMETYX® (cabozantinib . . . This content is for paid subscribers. Please click here to subscribe or here to log in.
The Small Stock That Refused to Kneel in Today’s Market

The Small Stock That Refused to Kneel in Today’s Market

Compugen Soaring in an Extremely Down Market The stocks' prices tumbled today except for very few and one of them is Compugen (CGEN). This firm announced good news; we wish it has chosen a better day for its announcement. Compugen's stock managed to rally as investor's enthusiasm was unlimited; knowing, in fact, what the success of Compugen immuno . . . This content is for …
How the Stock Prices of Firms Developing Treatments or Vaccines Have Started the Day

How the Stock Prices of Firms Developing Treatments or Vaccines Have Started the Day

NanoViricides and COVID-19 NanoViricides (NNVC), a development-stage nano-biopharmaceutical company with a proprietary and patented drug development focused on viral diseases, is among the few firms that are actively working on developing products that can treat the coronavirus disease COVID-19 which is caused by SARS-CoV-2 virus, or 2019-nCoV, now known also known as the . . . This content is for paid subscribers. Please click here to …
More About Moderna, Gilead and Forty Seven

More About Moderna, Gilead and Forty Seven

Moderna Therapeutics Among all the firms announcing their interest in working towards designing and producing a preventive vaccine for COVID-19 only Moderna (MRNA) has accomplished that job and delivered it to the health authorities to decide upon the next step. Moderna’s stock soared. The stock did not go up in expectation of the millions . . . This content is for paid subscribers. Please click here …
Regeneron and Moderna Are Both Outperforming Today

Regeneron and Moderna Are Both Outperforming Today

Regeneron, Moderna, and COVID-19 The spread of COVID-19, minute creatures that seem to be trying to defeat us, has been accused of bringing the market down over 1000 points yesterday. Investors who love the biotech stocks they carefully and accurately hand-picked should take advantage of the temporary market drop to buy more of their preferred stocks at bargain prices. In so doing, the cost of …
Why Regeneron Stock Is Soaring

Why Regeneron Stock Is Soaring

Regeneron Pharmaceuticals Stock is Rallying Regeneron Pharmaceuticals (REGN) stock outperformed last week gaining over $27. The stock’s soaring was not the outcome of the market’s outperformance, for several consecutive days, but because the . . . This content is for paid subscribers. Please click here to subscribe or here to log in.
A Synopsis of Some Biotech Companies’ Events

A Synopsis of Some Biotech Companies’ Events

Synopsis The way many bloggers are interpreting the quarterly and yearly biotech companies’ financial results seems unfair and has proven to be. Amgen Amgen (AMGN): The stock gained over $10 yesterday and is trading now at $231. Many bloggers continue to attack the firm, mourning the loss of their protective patents on its over 30 years’ old products and ignore the record . . . …
Could Nektar Product NKTR-214 Become a Blockbuster?

Could Nektar Product NKTR-214 Become a Blockbuster?

Nektar Therapeutics NKTR-214: A Blockbuster? Nektar Therapeutics (NKTR) published preclinical data of its immuno-oncology candidate NKTR-214 bempegaldesleukin (bempeg) succeeded in revealing the details of the drug’s actions that led to its successful outcome when used in monotherapy or in combination therapy in treating of various cancers.     The product, which is a CD122-preferential interleukin-2 . . . This content is for paid subscribers. Please click here to …
In a Market that Seems to Soar Today Our Eyes Are on These Biotech Firms

In a Market that Seems to Soar Today Our Eyes Are on These Biotech Firms

As the Market Seems to Soar Our Eyes Are on the Following Biotech Stocks: Amgen (AMGN): A rebounding is expected following an unwarranted decline.   Gilead Sciences (GILD): A lot of good news from the firm, including the firm’s investigational product remdesivir that demonstrated positive results in beating the coronavirus infection. Read yesterday's article posted
Why Moderna Stock Is Rallying

Why Moderna Stock Is Rallying

In the NEWS: Coronavirus Yesterday the CDC announced the first US case of coronavirus which has killed 17 and sickened hundreds of people in China. According to officials the first US case is of a very healthy 30 year old male currently being isolated at a medical center outside Seattle, WA so as not to pose a threat of contamination to the public. The CDC …
Midday January 16, 2020 Outperforming Prohost Picks

Midday January 16, 2020 Outperforming Prohost Picks

Outperforming Prohost Picks  January 16, 2020 at 11:30 am EST MRNA Trading at $21.35 UP $1.01 AMGN Trading at $243.50 UP $1.80 FTSV  Trading at $40.00 UP $3.20 RETA Trading at $217.01 UP $4.56 ALNY Trading at $119.26 UP $1.17 CGEN Trading at $5.96 UP $0.17 PTCT  Trading . . . This content is for paid subscribers. Please click here to subscribe or here to log in.